Journal of Clinical Oncology

Papers
(The H4-Index of Journal of Clinical Oncology is 130. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Attention to diet, exercise, and weight in the oncology clinic: Results of a national patient survey.1090
Weight changes according to treatment in a diverse cohort of breast cancer patients.800
The association of ATM alterations with clinical and molecular features in metastatic castration-resistant prostate cancer.789
Radiation therapy and associated cardiovascular outcomes in patients with Hodgkin’s lymphoma.683
The real-world BRCA1/2 germline mutations in Chinese solid tumors.618
A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS).553
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and lung cancer metastasis.552
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamou463
Clinical outcomes and prognostic factors in epithelial-myoepithelial carcinoma (EMC) of the breast.463
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists.458
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.458
Health state utility assessment for low-grade glioma.447
Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospect436
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.419
Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.400
Deep learning for 4D modeling of glioblastoma multiforme with tumor treating fields (TTFields) therapy.374
5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.374
Portal vein thrombosis in gastrointestinal cancers: Insights into prevalence and prognosis—A nationwide inpatient analysis 2018-2020.341
Percutaneous cryoablation of breast cancer metastases: Analysis of long-term single center experience, efficacy and outcomes.339
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.334
FOLFOX as a therapeutic option in patients with hepatic failure due to liver metastasis of gastrointestinal (GI) system malignancies: A case series.334
Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.333
Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.322
Spectrum of adipokines, batokines, myokines, and growth factors in blood serum of patients with various stages of lung cancer and with immunotherapy with PD-1/PD-L1 inhibitors.312
Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting.310
Expression of epidermal growth factor receptor (EGFR) in blood and tumor in patients with breast carcinoma: Prognostic analysis.305
Comprehensive cancer genomics-based screening of new therapeutic targets and biomarkers for lung cancer.304
Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.291
Genetic and treatment risks for diabetes mellitus (DM) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime (SJLIFE) cohorts.279
Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.278
Genome-wide association study to reveal novel germline markers of melanoma survival.277
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.271
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.264
Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.263
Association of changes of pro-inflammatory markers with physical function in women with breast cancer receiving chemotherapy.258
Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis.257
Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphom257
Right-censoring bias in trials shared at the Project Data Sphere platform.255
Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.254
Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology253
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.252
A symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) to maintain physical function.240
Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational s238
A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-237
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers.235
Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients 234
Effects of metabolic syndrome on cognitive outcomes in long-term survivors of childhood cancer.233
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.232
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analy231
Treatment-specific risk of second malignancies in five-year survivors of diffuse large B-cell lymphoma.229
Overall and progression-free survival in young breast cancer patients with low muscle mass and density.229
Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth facto227
NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.226
Preference-weighted quality of life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT).225
A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX216
Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.214
Five-day accelerated partial breast irradiation (APBI) using intensity modulated radiation therapy (IMRT) in stage 0-II breast cancer: A report of 214 cases with up to 39 month follow-up.209
Liquid biopsy for baseline evaluation of tumor burden in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A proof of principle study.203
An investigation into the impact of next generation sequencing on the use of targeted treatments in glioblastoma.201
Racial, ethnic, and socioeconomic disparities in diagnosis, treatment, and survival of patients with breast cancer.201
Descriptive study of the therapeutic aggressiveness in oncology patients in the hospital area of Huelva.198
Genetic alterations in MSS and TMB-H Chinese colorectal cancer patients.197
Association of electronic-health record (EHR)-derived race with BRCA testing in patients (pts) with breast cancer (BC) with similar genetic ancestry (GA) in a clinicogenomic database (CGDB).196
The relationships between cancer diagnosis/prognosis awareness and quality of life, anxiety, and depression in Chinese gastroesophageal cancer patients: A cross-correlation analysis.196
A national study of allogeneic stem cell transplantation for adults with acute myeloid leukemia: Do gender and age above 70 years matter?195
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.194
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.190
Feasibility of functional evaluation in older adults with gastroesophageal cancer using fitness trackers.190
Liver steatosis and fibrosis as independent prognostic factors affecting survival in colorectal cancer with liver metastases.189
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.189
Ground-glass opacity showed response to immunotherapy in cancer patients.187
The role of exosomal LINC00853 in gastric cancer progression.186
Expression of claudin 18.2 in peritoneal metastasis (PM) of gastric cancer.186
Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?186
The power of glycobiology: Precision of polyp detection using glycoproteomic biomarkers.181
Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.180
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.179
Assessing disparities in pancreatic cancer outcomes in African Americans.177
Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.175
Genetic testing of Japanese patients with serrated polyposis syndrome: A multicentric study.175
Characterizing the rare abdominal neoplasms of peritoneum, retroperitoneum, and overlapping sites of peritoneum and retroperitoneum: A review of NCDB database.175
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies.174
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.172
Assessing the impact of hypercalcemia of malignancy on clinical outcomes in cancer patients admitted with acute pancreatitis.172
Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.171
Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer.170
Characterization of BCL-2 alternative proteins and outcome in patients with peripheral T-cell lymphoma (PTCL).168
Identification of TGFBR2 mutation as a negative predictor of immunotherapy in NSCLC.168
Breast cancer as seen at the Nairobi Hospital.167
Dermatologic diagnoses in oncology patients of color on anticancer therapy: Five-year retrospective review of outpatient dermatology consultations.165
Risks of Organ Preservation in Rectal Cancer: Beyond Distant Metastases, Ultimate Local Failure Can Also Be a Problem165
Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.164
Prognostic impact of inflammatory profiling during and after multimodal treatment for stage III NSCLC.164
Evaluating Accuracy of Medical Information Distribution Regarding Risk of COVID-19 Infections and Childhood Cancer Survivors164
Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age163
Interactive online skin cancer training game “Whack-a-Mole” assesses training strategies and real-time feedback on melanoma identification among U.S. adults.163
TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.161
Cellworks Omics Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance.159
The timeliness of lung cancer care: A systematic review of systematic/scoping reviews on risk factors and interventions.159
Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.155
Overall survival after perioperative chemotherapy in the management of pulmonary metastasis in osteosarcoma.155
Mir-34a as predictor of immunotherapy efficacy in NSCLC patients.154
Implementation of a virtual tumor board through VA National TeleOncology service.152
Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.152
Efficacy of alpelisib (ALP) + fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2- advanced breast cancer (ABC).151
Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.150
Expanding diversity in colorectal cancer studies with a focus on Hispanic and Latino participant enrollment.150
Abemaciclib dose escalation to maintain intensity (ADE-MI).150
Impact on biomarker documentation in community oncology by optimizing clinical decision support.147
Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach.147
Factors associated with delays in care of suspicious lung nodules at an academic medical center.147
Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2.146
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).144
Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports.144
Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis.143
Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, P143
Disparities in incidence and mortality of hematologic cancers in Southeast Asia: A 2020 analysis.141
Breast cancer outcomes and treatment toxicity in geriatric patients compared to other patients at the Cancer Disease Hospital in Zambia.141
NSQIP audit of enhanced recovery after surgery protocols for radical cystectomy.140
Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA.140
Incorporating precision oncology in everyday clinical practice: First two years of comprehensive genomic profiling (CGP) testing experience in Croatia.139
Financial toxicity (FT), quality of life (QoL), and medication adherence patient-reported outcomes (PROs) in CLL on first-line (1L) oral oncolytics.139
A novel multi-cancer screening approach based on screening objectives, cancer occurrence mechanism, and cost modeling.137
A phase I/II trial of neoadjuvant pegylated arginine deiminase (ADI-PEG 20) with ifosfamide and radiotherapy in soft tissue sarcomas (STS) of the trunk or extremity.136
Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market.136
Efficacy of mammography screening in women aged 40–49 years: An updated systematic review and meta-analysis.135
Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study.134
Implementation of video assisted point-of-care germline genetic education and testing for patients with peri-diagnostic pancreatic cancer.134
Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in patients with head and neck cancer (HNSCC).133
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.130
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.130
0.086467981338501